Phosphodiesterase Enzyme (PDE) Inhibitors Market to Register Remarkable Growth due to Favorable Reimbursement Policies, Global Industry Report, Size Estimation, Share, Analysis, Top Companies Revenues by 2026
Phosphodiesterase are a diverse family of enzymes (11 isoenzymes) that play a key role in regulating intracellular levels of secondary messengers – cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate. These enzymes identified to be pharmacologically active in the 1950s, hydrolyses cyclic nucleotides to treat various diseases such as cardiovascular, respiratory, and erectile dysfunction. Distinct distribution of all types of isoenzymes has provided possibilities for selective target therapies.
Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/172
The global phosphodiesterase enzyme inhibitors market can be better analyzed by classifying it into two classes as selective phosphodiesterase enzyme inhibitors and non-selective phosphodiesterase enzyme inhibitors. Theophylline and papaverineare the two most commonly used non-selective phosphodiesterase enzyme inhibitors for treating a range of diseases (bronchodilation, cardiac disorder, etc.). Advent of selective phosphodiesterase enzyme inhibitors have made a great impact in the medical treatment sector. Increasing understanding of the individual PDE isoforms is expected to result in the emergence of better therapeutic drugs. Viagra (Sildenafil) is the best example to substantiate the success and impact of PDE inhibitors.
The global phosphodiesterase enzyme inhibitors market is therefore analyzed based on the drug class and application as follows:
- Drug Class
- Selective PDE inhibitors
- Non-selective PDE inhibitors
- Selective PDE inhibitors
- Cardiovascular Disease
- Respiratory Disease
- Erectile Dysfunction
- Pulmonary Hypertension
- Benign Prostate Hyperplasia
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/172
The global phosphodiesterase enzyme inhibitors market is majorly driven by development of PDE-5 inhibitors of blockbuster drugs in these segment.
Increasing product developments to further improvise the phosphodiesterase enzyme inhibitors market outlook
The global phosphodiesterase enzyme inhibitors market has recently gained traction on account of the blockbuster PDE 5 inhibitor brands, Viagra and Cialis. This has also encouraged pharmaceutical companies to research on other PDE inhibitor class. In addition, research on extended use of approved PDE inhibitors is expected to benefit drugs in the long term and contribute to growth of the PDE inhibitors market.
- In 2017, researchers from the John Hopkins University reviewed trials of PDE-5 inhibitors in pediatric patients with pulmonary hypertension. The researchers concluded that PDE-5 inhibitors can be safely prescribed to infants, neonates and children with primary and secondary pulmonary hypertension.
- PDE-5 inhibitor sildenafil developed for treating angina, was also found to be effective in erectile dysfunction and now is observed to benefit stroke patients. Researchers at Karolinska Institutet, Sweden reported in March 2017 that PDE-5 inhibitors prescribed for erectile dysfunction can lower the risk of death in men who have suffered one heart attack in their lifetime.
- Pfizer, Inc. received FDA approval for its PDE-4 inhibitor Crisaborole (Eucris) in December 2016 for the treatment of mild to moderate atopic dermatitis. Eucrisa is the first non-steroidal topical monotherapy for skin disorder.
Such product developments are expected to drive the global PDE inhibitors market growth in the near future.
Product developments in the U.S., Japan, and Europe are facilitating market growth. However, increasing number of product approvals in emerging economies such as India, China, Brazil, Russia, Argentina, and Indonesia are projected to favor demand in Asia Pacific and Latin America markets. Increasing healthcare expenditure and large population are some of the factors supporting growth of the PDE inhibitors market in these nations. However, stringent regulatory guidelines and challenges with product approvals are likely to hamper the market growth to some extent.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/phosphodiesterase-enzyme-inhibitors-market-172
Some of the key players operating in the global phosphodiesterase enzyme inhibitors market include Pfizer, Inc., AstraZeneca plc., Bayer AG, Eli Lilly & Company, Celgene Corporation, and Mist Pharmaceuticals.About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire